Category - News

Developments

Enrollment reaches halfway in IntelGenx Phase 2a Montelukast VersaFilm AD trial

Patient enrollment in the IntelGenx (TSX:IGX; OTCQB:IGXT) ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) has reached the halfway mark. This...

September 8, 2022

Markets

Cantor starts Asensus Surgical at OW; PT $1.50

Cantor Fitzgerald initiated coverage of Asensus Surgical (NYSE American:ASXC) with an “overweight” rating and price target of $1.50. The stock closed at 53 cents on Sept. 7. Asensus is a robotic-assisted surgery company...

September 8, 2022

Markets

Cantor starts Actinium Pharma at OW; PT $20

Cantor Fitzgerald launched coverage of Actinium Pharmaceuticals (NYSE American:ATNM) with an “outperform” rating and $20 price target. The stock closed at $7.51 on Sept. 7. Actinium is a clinical-stage biopharmaceutical...

September 8, 2022

Developments

VoxNeuro, Boston U collaborating in concussion, AD studies

Closely-held VoxNeuro, a software-as-a-medical-device brain (SaMD) health company, is collaborating with Boston University to launch two studies that will evaluate the company’s cognitive health assessment platform in...

September 7, 2022

Developments

Brickell Biotech changes name to Fresh Tracks Therapeutics

Brickell Biotech (NASDAQ:BBI) changed its name to Fresh Tracks Therapeutics, with a new stock symbol, FRTX, effective at the NASDAQ opening on Sept. 8, 2022. The unveiling of the company’s rebranding reinforces...

September 7, 2022

Developments

Europe clears Rhythm’s IMCIVREE for obesity and hunger in BBS

The European Commission has expanded the marketing authorization for Rhythm Pharmaceuticals’ (NASDAQ:RYTM) IMCIVREE (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically...

September 7, 2022

Developments

Hepion Pharmaceuticals initiates Phase 2b ASCEND-NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) screened the first subject in its ASCEND-NASH clinical trial being conducted at up to 121 sites in seven countries, including 85 sites in the U.S. The Phase 2b, randomized, multi...

August 31, 2022

Markets

Piper starts Miromatrix Medical at OW; PT $8

Piper Sandler launched coverage of Miromatrix Medical (NASDAQ:MIRO) with an “overweight” rating and $8 price target. The stock closed at $2.92 on Aug. 30. Miromatrix has developed a proprietary perfusion technology...

August 31, 2022

Markets

Dawson James starts Smart for Life at buy; PT $8

Dawson James initiated coverage of Smart for Life (NASDAQ:SMFL) with a “buy” rating and $8 price target. The stock closed at 53 cents on Aug. 26. The company’s goal is the development, marketing, manufacturing...

August 29, 2022

Developments

HCW ups Calithera to buy on steady progress of clinical programs

H.C. Wainwright upgraded Calithera Biosciences (NASDAQ:CALA) to “buy” from “neutral” with a 12-month price target of $8, citing two ongoing clinical development programs that are expected to provide data updates in the...

August 29, 2022

Category - News

Subscribe